RRC ID 52271
著者 Tsubouchi H, Onomura H, Saito Y, Yanagi S, Miura A, Matsuo A, Matsumoto N, Nakazato M.
タイトル Ghrelin does not influence cancer progression in a lung adenocarcinoma cell line.
ジャーナル Endocr J
Abstract Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (GHSR), is produced in the human stomach. Although ghrelin has therapeutic potential for cancer cachexia, ghrelin treatment may have a concern about accelerating cancer progression. Here, using the human lung adenocarcinoma cell line HLC-1, we investigated the effects of ghrelin on molecular mechanisms linked to cancer progression, including cell viability, proliferation, resistance to apoptosis, and mitochondrial activity. Both types of mouse alveolar epithelial cells (types I and II) expressed the GHSR, as did the human normal airway cell lines BEAS-2B and HLC-1. Treatment with ghrelin (10-2, 10-1, 1, 10 μM) did not affect cell viability or proliferation. Pretreatment of HLC-1 cells with ghrelin (10 μM) did not affect resistance to paclitaxel-induced apoptosis. The parameters of mitochondrial respiration, including basal respiration, proton leak, ATP production, maximal respiration, spare respiratory capacity, and non-mitochondrial respiration, of the HLC-1 cells pretreated with or without ghrelin were unchanged. Taken together, ghrelin does not influence cancer progression in lung adenocarcinoma cells.
巻・号 64(Suppl.)
ページ S41-S46
公開日 2017-1-1
DOI 10.1507/endocrj.64.S41
PMID 28652543
MeSH Adenocarcinoma / drug therapy Adenocarcinoma / pathology* Apoptosis / drug effects Cell Line, Tumor Cell Proliferation / drug effects* Cell Survival / drug effects* Disease Progression Ghrelin / administration & dosage Ghrelin / therapeutic use* Humans Lung Neoplasms / drug therapy Lung Neoplasms / pathology* Mitochondria / drug effects
IF 1.952
引用数 2
リソース情報
ヒト・動物細胞 HLC-1(RCB0083)